GeneralConnection.com ➔ Dictionary
Dictionary Search

factor xi

Synonyms

Noun

1. plasma thromboplastin antecedent

2. factor XI, coagulation factor, clotting factor

Usage
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism - Nature
Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS - American Heart Association Journals
Anti-Factor XI Anticoagulants: Breakthrough or Bust? - Medscape
New Factor XI inhibitor shows superior safety in treating atrial fibrillation - News-Medical
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders - Business Wire
NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear - TCTMD.com
Factor XI Inhibitors Are a Safer Option for Stroke Prevention | ACC 2025 - Managed Healthcare Executive
Asundexian versus Apixaban in Patients with Atrial Fibrillation - The New England Journal of Medicine
Factor Xa and Factor XI Inhibitors: What Lies Ahead for Anticoagulants - The Cardiology Advisor
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patient - GlobeNewswire
Novartis pays $925M to reel in a startup it helped launch - BioPharma Dive
Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors - Frontiers
Abelacimab: the next frontier in safer anticoagulation therapy - Drug Target Review
What Now for Factor XI Inhibitors in AF? - Medscape
Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition - Business Wire
Regeneron says study data support big bet on new blood thinners - BioPharma Dive
Case Report: Allelic and biallelic variants in coagulation factor XI cause factor XI deficiency - Frontiers
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - GlobeNewswire
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban - GlobeNewswire
Factors XI and XII as Targets for New Anticoagulants - Frontiers
Factor XI, a potential target for anticoagulation therapy for venous thromboembolism - Frontiers
Regeneron anticoagulant bests enoxaparin, matches Eliquis in phase 2 trial - Fierce Biotech
New Data Highlights Abelacimab’s Safety Advantage in Atrial Fibrillation - Pharmacy Times
The effect of coagulation traits on the risk of retinal vein occlusion: a mendelian randomization study - Nature
Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence - Frontiers
Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate - Fierce Biotech
Anthos Therapeutics Unveils Additional Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating that the Factor XI Inhibitor Abelacimab was Associated with Remarkably Low Levels of Periprocedural Bleeding in Patients with Atrial Fibrillation - Business Wire
Novartis buys Blackstone's Anthos for up to $3.1 billion - Reuters
Regeneron forges ahead in factor XI despite field’s mixed results - Endpoints News
Injectable Anticoagulant Substantially Cuts Bleeding Risk in Afib - MedPage Today
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation - The New England Journal of Medicine
Asundexian for AF? More Details on the Sinking of OCEANIC-AF - TCTMD.com
ISTH announces launch of new global education initiative in factor XI/XIa inhibition - PR Newswire
Anthos spells out benefits of abelacimab in quest for safer blood thinners - FirstWord
New class of anticoagulant found to ‘overwhelmingly’ reduce bleeding events in patients with atrial fibrillation - The Pharmaceutical Journal
Anesthetic Implications of Factor XI Deficiency: A Clinical Case Study and Review of Literature - Cureus
Clinical Trial Opportunity for Afib Patients Who Don’t Take an Anticoagulant - National Blood Clot Alliance
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio - geneonline.com
Abstract 4143980: Bleeding with the FXI Inhibitor Abelacimab compared with Rivaroxaban in Patients on Antiplatelet therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial - American Heart Association Journals
Effects of storage time and temperature on coagulation factor and natural anticoagulant activities in healthy individuals - Nature
Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab - AJMC
Novartis nets potential first-in-class medicine in new cardiovascular acquisition - European Pharmaceutical Review
Anthos' detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer's failed? - Endpoints News
Abelacimab reduces bleeding risk compared to rivaroxaban in atrial fibrillation - 2 Minute Medicine
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition - BioSpace
Jan 24, 2025 This Week in Cardiology Podcast - Medscape
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion - Business Wire
Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients - News-Medical
Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos - Endpoints News
Novartis Welcomes Abelacimab Back Into The Fold With Anthos Acquisition - insights.citeline.com
Regeneron advances anticoagulant antibody pair to late-stage testing - FirstWord
Pharmacology and Clinical Development of Factor XI Inhibitors | Circulation - American Heart Association Journals
Biologic demonstrates “tremendous” potential advance in atrial fibrillation - European Pharmaceutical Review
New data reveal how Bayer's asundexian failed to prevent strokes, imperiling $5.5B blockbuster hopes - Fierce Biotech
Siddharth Patel, MD, MPH: Abelacimab Could Help Reduce Procedure-Related Bleeding - HCPLive
Coagulation cascade and Factor XI inhibitors. FXI(a), factor XI(a);... - ResearchGate
Further strong data for Anthos’ abelacimab in atrial fibrillation - The Pharma Letter
Christian T. Ruff, MD, MPH: Abelacimab Limits Bleeding Events in AZALEA–TIMI 71 Trial - HCPLive
Figure 1 Mechanism of action of factor XI(a) inhibitors. Adapted... - ResearchGate
A Novel Antithrombotic Mechanism Mediated by the Receptors of the Kallikrein/Kinin and Renin–Angiotensin Systems - Frontiers
What Is the Future of Factor XI Inhibitors? - American Heart Association Journals
Role of factor XI in hemostasis (see text). Factor XI plays an... - ResearchGate
Stopping abelacimab may not be necessary before invasive procedures - Healio
FIGURE 1: Rotational thromboelastometry (ROTEM) traces of the clinical... - ResearchGate
Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial - AJMC
New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors - American Heart Association Journals
Factor XI Inhibitors: The Promise of a Truly Safe Anticoagulant? - Medscape
Q&A: Failure of OCEANIC-AF trial may not dampen future of factor XI/XIa inhibitors - Healio
‘Imitation is best form of flattery’: Regeneron CEO comments on Amgen’s Eylea biosimilar - Endpoints News
Role of factor XI in thrombosis. Factor XI is particularly important... - ResearchGate
Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial - Nature
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes - American Heart Association Journals
New anti-clotting medication reduces bleeding among people with atrial fibrillation - www.heart.org
Liver-derived factor XI protects against HFpEF - Nature
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
Feedback activation of factor XI by thrombin does not occur in plasma - PNAS
Abelacimab for Prevention of Venous Thromboembolism - The New England Journal of Medicine
Factor XI inhibitor for AF drastically reduces bleeding vs. rivaroxaban in phase 2 trial - Healio
Genetically Determined FXI (Factor XI) Levels and Risk of Stroke - American Heart Association Journals
A Case of Myxedema Edema in a Patient With Factors XI and XII Deficiency and Sepsis: Unveiling Complications and Management Strategies - Cureus
-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped β - PNAS
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis - The New England Journal of Medicine
Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma - PNAS
Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure - Science | AAAS
Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients? | Circulation - American Heart Association Journals
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI - PNAS
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale - Nature
Mechanism of action for heparins. LMWH—low molecular weight heparin;... - ResearchGate
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation - Business Wire
AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa - American Heart Association Journals
Merging Biocatalysis, Flow, and Surfactant Chemistry: Innovative Synthesis of an FXI (Factor XI) Inhibitor - ACS Publications
Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI) - American Heart Association Journals
Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial - American Heart Association Journals
Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions - Diagnostic and Interventional Cardiology
OCEANIC-AF study stopped early due to lack of efficacy - Bayer
Asundexian’s Lack of Efficacy Sinks OCEANIC-AF - TCTMD.com
The intrinsic pathway of coagulation also referred to as the contact... - ResearchGate
What Is the Future of Factor XI Inhibitors? - American Heart Association Journals
Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis - Presume - 2022 - Journal o - Wiley Online Library
Merck, seeking XI factor in race with Bayer, gets FDA fast-track tag for anticoagulant - Fierce Biotech
Foreign Language Equivalents
Foreign Language Equivalents of 'factor xi'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
factor ix,   faxtor xi,   facror xi,   facter xi,   actor xi,   factor xxi,   factor ci,   factoe xi,   factor xi,   facto rxi,   factoor xi,   factpr xi,   factor xii,   fatcor xi,   factor i,   facor xi,   factor xu,   favtor xi,   factr xi,   facotr xi,   factot xi,   facctor xi,   factor x,   afctor xi,   fctor xi,   factir xi,   factro xi,   factorx i,   factor xo,   factor zi,   facyor xi,   dactor xi,   factorxi,   fsctor xi,   facttor xi,   gactor xi,   ffactor xi,   facto xi,   fcator xi,   faactor xi,   factorr xi,   fator xi
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z